jetcityimage
- Eli Lilly's (NYSE:LLY) Mounjaro and Zepbound, which both have the active ingredient tirzepatide and are used for diabetes and weight loss, respectively, will be in shortage through at least the end of Q2.
- The U.S. FDA Wednesday updated the drug shortage status for the two medications. Only one dosage strength of Mounjaro and Zepbound have normal availability.
- Tirzepatide, a dual GIP/GLP-1 receptor co-agonist, has proven to be one of Lilly's most successful recent drug launches. While the drug more recently won approval as a weight loss therapy (Zepbound), Mounjaro was being used off label for weight loss prior.
- Novo Nordisk's (NVO) competing GLP-1 weight loss therapy, Wegovy (semaglutide), is also in shortage, with four out of five dosage strengths having limited availability. The FDA said that the estimated shortage duration is to be determined.
- Ozempic, which also contains semaglutide but is approved for diabetes, is not in shortage.
More on Eli Lilly
- Wall Street Lunch: Lilly In Limelight
- Eli Lilly: Three Threats To Its Huge Rally
- Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data
- Eli Lilly obesity therapy succeeds in late-stage trials for sleep disorder
- GLP-1s benefit Parkinson’s: Barclays sees implications across biopharma